Usual Treatment

Phase 3Small molecule

UUniversity Hospital, Grenoble

Usual Treatment is one of 157 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

156

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

EpilepsyActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Major Depressive DisorderActive, not recruiting

Interstitial Lung DiseasePreclinical

Active, not recruiting

EpilepsyPhase 3

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 3

Active, not recruiting

Major Depressive DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Elavil

AstraZeneca

Phase 3

2 3

Daliresp

AstraZeneca

Phase 3

1 4

Latuda

SSunovion Respiratory Development Inc.

Phase 3

3 5

SAGE-217

Biogen

Phase 3

7 6

Risperdal

WWim Janssens

Phase 3

2 7

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 8

Psilocybin

COMPASS Pathways

Phase 3

11 9

Fetzima

AbbVie

Phase 3

9 10

Brenipatide

Eli Lilly

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Idiopathic Pulmonary Fibrosis

NCT07299695

Q1 2029

N/ARecruiting

Interstitial Lung Disease

NCT07466420

Clinical

Trials by Indication[1]

Major Depressive Disorder1 trial

A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features

Unknown status·SShanghai Mental Health Center·N/A·NCT04209166·780 enrolled

Epilepsy1 trial

Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy

Completed·UUniversity Hospital, Grenoble·Phase 3·NCT02076698·62 enrolled

Interstitial Lung Disease1 trial

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

Recruiting·—·N/A·NCT07466420·100 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Recruiting·AArgyrios Tzouvelekis·Phase 3·NCT07299695·196 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Usual Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Usual Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Usual Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Grenoble company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Grenoble

Usual Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Trials by Indication[1]

Major Depressive Disorder1 trial

Epilepsy1 trial

Interstitial Lung Disease1 trial

Idiopathic Pulmonary Fibrosis1 trial

References

Drug Info

Quick Facts

Related News